[Skip to Content]
[Skip to Content Landing]
Article
January 1940

EVALUATION OF THERAPY IN MYASTHENIA GRAVIS

Author Affiliations

PHILADELPHIA

From the Neurologic Division of the Montefiore Hospital for Chronic Disease, New York.

Arch Intern Med (Chic). 1940;65(1):60-77. doi:10.1001/archinte.1940.00190070070005
Abstract

The disease entity known as myasthenia gravis was first described by Willis1 in the seventeenth century. Although this condition is relatively easy to recognize clinically, its cause has remained obscure. Pathologically in many cases there are variable degrees of nonspecific degenerative muscle atrophy. In more than 50 per cent of cases focal collections of small round cells have been observed in muscles and other organs. These small foci of cells have been termed "lymphorrhages" and when present are diagnostically significant. A relatively large number of cases have been reported in which thymic neoplasms existed. The conspicuous symptomatic features of myasthenia gravis are excessively rapid fatigability of muscles in action and quick restitution of function on relaxation. The muscular exhaustibility may be elicited in the form of a characteristic electrical reaction which has been termed the Jolly reaction.

In this article no effort will be made to discuss in detail

References
1.
Willis, cited by Guthrie, G. L.:  "Myasthenia Gravis" in the Seventeenth Century ,  Lancet 1:330 ( (Jan. 31) ) 1903.
2.
Keschner, M., and Strauss, I.:  Myasthenia Gravis ,  Arch. Neurol. & Psychiat. 17:337 ( (March) ) 1927.
3.
The form of extract of the anterior lobe of the pituitary gland used in this study was antuitrin.
4.
Simon, H. E.:  Myasthenia Gravis ,  J. A. M. A. 104:2065 ( (June 8) ) 1935.
5.
Remen, L.:  Zur Pathogenese und Therapie der Myasthenia gravis pseudoparalytica ,  Deutsche Ztschr. f. Nervenh. 128:66, 1932.
6.
Boothby, W. M.:  Myasthenia Gravis: A Preliminary Report on the Effect of Treatment with Glycine ,  Proc. Staff Meet., Mayo Clin. 7:557 ( (Sept. 28) ) 1932.
7.
Edgeworth, H.:  A Report of Progress on the Use of Ephedrine in a Case of Myasthenia Gravis ,  J. A. M. A. 94:1136 ( (April 12) ) 1930.
8.
Boothby, W. M.:  Myasthenia Gravis: The Effect of Treatment with Glycine and Ephedrine ,  Arch. Int. Med. 53:39 ( (Jan.) ) 1934.
9.
Dale, H.:  Chemical Transmission of the Effects of Nerve Impulses ,  Brit. M. J. 1:835 ( (May 12) ) 1934.
10.
Loewi, O.:  Ferrier Lecture on Problems Connected with the Principle of Humoral Transmission of Nervous Impulses ,  Proc. Roy. Soc., London, s.B 118: 299 ( (Sept. 2) ) 1935.
11.
Walker, M. B.:  Treatment of Myasthenia Gravis with Physostigmine ,  Lancet 1:1200 ( (June 2) ) 1934.
12.
Pritchard, E. A. B.:  The Use of "Prostigmin" in the Treatment of Myasthenia Gravis ,  Lancet 1:432 ( (Feb. 23) ) 1935.
13.
Viets, H. R., and Schwab, R. S.:  Prostigmin in the Diagnosis of Myasthenia Gravis ,  New England J. Med. 213:1280 ( (Dec. 26) ) 1935.
14.
Schwab, R. S., and Viets, H. R.:  Prostigmin Test in Myasthenia Gravis ,  New England J. Med. 219:226 ( (Aug. 18) ) 1938.
15.
Laurent, L. P. E., and Walker, M. B.:  Prostigmin and Its Analogues in Myasthenia Gravis ,  Lancet 1:1457 ( (June 27) ) 1936.
16.
Boothby, W. M.:  Myasthenia Gravis ,  Tr. A. Am. Physicians 51:188, 1936.
17.
Macfarlane, J. W.:  Myasthenia Gravis: Its Treatment by Combination of Prostigmin and Glycine-Ephedrine Therapy ,  Glasgow M. J. 128:7 ( (July) ) 1937.
18.
Laurent, L. P. E., and Walther, W. W.:  Influence of Large Doses of Potassium Chloride on Myasthenia Gravis ,  Lancet 1:1434 ( (June 22) ) 1935.
×